Herrera-Ojeda José L, Blanco-Palma Ray S, Chávez-Tapia Norberto C, Uribe Misael, Montalvo-Javé Eduardo E, Nuño-Lámbarri Natalia
Traslational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.
Department of Surgery Faculty of Medicine, The National Autonomous University of Mexico (UNAM), Mexico City, Mexico.
J Endocrinol Invest. 2025 Jun 27. doi: 10.1007/s40618-025-02621-5.
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic β-cells, leading to significant endogenous insulin deficiency. In this context, inflammation plays a crucial role in the pathogenesis of the disease. Traditionally, insulin resistance has been associated with Type 2 Diabetes Mellitus (T2DM); however, recent studies have shown that it also occurs in a significant proportion of T1DM patients. Regarding the prevalence of Non-Alcoholic Fatty Liver Disease associated with metabolic dysfunction (MASLD), variations are observed depending on the studied population and diagnostic method used, although there has been a global increase in this condition in T1DM patients. MASLD is closely linked to insulin resistance, both hepatic and peripheral, suggesting that MASLD progression is associated with worsening insulin resistance. The relationship between both pathologies is bidirectional, as the presence of one can accelerate the progression of the other. When both coexist, the natural history of both diseases is altered, increasing the risk of complications and worsening patient prognosis.
1型糖尿病(T1DM)是一种自身免疫性疾病,其特征是胰腺β细胞被破坏,导致严重的内源性胰岛素缺乏。在这种情况下,炎症在该疾病的发病机制中起关键作用。传统上,胰岛素抵抗与2型糖尿病(T2DM)相关;然而,最近的研究表明,它也在相当比例的T1DM患者中出现。关于与代谢功能障碍相关的非酒精性脂肪性肝病(MASLD)的患病率,尽管T1DM患者中这种情况在全球范围内有所增加,但根据所研究的人群和使用的诊断方法会观察到差异。MASLD与肝脏和外周的胰岛素抵抗密切相关,这表明MASLD的进展与胰岛素抵抗的恶化有关。两种病理之间的关系是双向的,因为一种疾病的存在会加速另一种疾病的进展。当两者共存时,两种疾病的自然病程会改变,增加并发症的风险并恶化患者的预后。
J Endocrinol Invest. 2025-6-27
World J Gastroenterol. 2025-5-28
J Obes Metab Syndr. 2025-6-20
Diabetes Obes Metab. 2025-6-19
Cochrane Database Syst Rev. 2016-6-7
Cochrane Database Syst Rev. 2016-3-2
Cochrane Database Syst Rev. 2017-12-22
JHEP Rep. 2024-8-9
Nat Commun. 2024-5-29
Biomed Pharmacother. 2024-6
Biomolecules. 2024-4-13
Cardiovasc Diabetol. 2024-2-10